|
|
Borna disease virus |
| Table of Contents |
- General Information
- NCBI Taxonomy ID
- Vaccine Related Pathogen Genes
- p10
(Protective antigen)
- Vaccine Information
- Borna Disease Virus BDV-N
- rORFV-p40(Borna disease virus)
- References
|
| I. General Information |
| 1. NCBI Taxonomy ID: |
|
12455 |
| II. Vaccine Related Pathogen Genes |
|
1. p10 |
-
Gene Name :
p10
-
Sequence Strain (Species/Organism) :
Borna disease virus
-
NCBI Protein GI :
AAX09334
-
Other Database IDs :
CDD:115187
-
Taxonomy ID :
1714621
-
Protein Name :
p10
-
Protein pI :
10.74
-
Protein Weight :
7848.852
-
Protein Length :
126
-
Protein Note :
Borna disease virus P10 protein; pfam06515
-
Protein Sequence : Show Sequence
>AAX09334.1 p10, partial [Borna disease virus 1]
VRANGTRPHQSGKIPGGRRRSPDTTTGTIGVTKTTEGPKECIDPTSRPAPEGPQEEPLHDLRPRPANRKG
AAVE
-
Molecule Role :
Protective antigen
-
Molecule Role Annotation :
(Hashimoto et al., 2003)
|
| III. Vaccine Information |
 |
|
 |
|
|
|
|
1. Borna Disease Virus BDV-N |
| a. Type: |
| Recombinant vector vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Mouse |
| d. Antigen |
| Borna Disease Virus Nucleoprotein (Hausmann et al., 2005) |
| e. Vector: |
| Parapoxvirus D1701-VrVp40 (Hausmann et al., 2005) |
| f. Immunization Route |
| intramuscular (1st dose) and intraperitoneal (2nd dose |
| g. Description |
| BVD vaccine expressing nucleoprotein protects wild type and perforin deficient mice against BVD challenge. (Hausmann et al., 2005) |
|
|
|
 |
|
 |
|
|
|
|
|
|
|
|
|
2. rORFV-p40(Borna disease virus) |
| a. Vaccine Ontology ID: |
| VO_0004769 |
| b. Type: |
| Recombinant vector vaccine |
| c. Status: |
| Research |
| d. Host Species for Licensed Use: |
| Baboon |
| e. Preparation |
| The highly attenuated Orf virus strain D1701 was used to generate a recombinant virus (D1701-VrVp40) expressing nucleoprotein p40 of Borna disease virus (Henkel et al., 2005). |
| f. Immunization Route |
| Intramuscular injection (i.m.) |
| g.
Rat Response |
- Vaccination Protocol:
The rats were immunized at an age of 4 to 5 weeks in 2-week intervals by intramuscular application of D1701-VrVp40 (Henkel et al., 2005).
- Vaccine Immune Response Type:
VO_0000287
- Challenge Protocol:
2 weeks after the last immunization 5 ×103 to 10 ×103 FFU of BDV were used for intracerebral challenge infection (Henkel et al., 2005).
- Efficacy:
Rats immunized with D1701-VrVp40 exhibited protection against Borna Disease, and virus clearance from the infected brain was demonstrated in immunized animals. Even 4 and 8 months after the last immunization, all immunized animals were still protected against the disease (Henkel et al., 2005).
|
|
|
|
|
|
|
|
|
| IV. References |
1. Hashimoto et al., 2003: Hashimoto Y, Chen HS, Cunningham C, Malik TH, Lai PK. Two major histocompatibility complex class I-restricted epitopes of the Borna disease virus p10 protein identified by cytotoxic T lymphocytes induced by DNA-based immunization. Journal of virology. 2003; 77(10); 6076-6081. [PubMed: 12719601].
2. Henkel et al., 2005: Henkel M, Planz O, Fischer T, Stitz L, Rziha HJ. Prevention of virus persistence and protection against immunopathology after Borna disease virus infection of the brain by a novel Orf virus recombinant. Journal of virology. 2005; 79(1); 314-325. [PubMed: 15596826].
|
|
